PMID- 22198207
OWN - NLM
STAT- MEDLINE
DCOM- 20120427
LR  - 20171116
IS  - 1872-7980 (Electronic)
IS  - 0304-3835 (Linking)
VI  - 318
IP  - 2
DP  - 2012 May 28
TI  - Resistance of leukemic stem-like cells in AML cell line KG1a to natural killer 
      cell-mediated cytotoxicity.
PG  - 173-9
LID - 10.1016/j.canlet.2011.12.017 [doi]
AB  - Leukemic stem cells (LSCs) play the central role in the relapse and refractory of 
      acute myeloid leukemia (AML) and highlight the critical need for the new 
      therapeutic strategies to directly target the LSC population. However, relatively 
      little is known about the unique molecular mechanisms of drug and natural killer 
      cells (NK)-killing resistance of LSCs because of very small number of LSCs in 
      bone marrow. In this study, we investigated whether established leukemia cell 
      line contains LSCs. We showed that KG1a leukemia cell line contained leukemic 
      stem-like cells, which have been phenotypically restricted within the 
      CD34(+)CD38(-) fractions. CD34(+)CD38(-) cells could generate CD34(+)CD38(+) 
      cells in culture medium and had renewal function. Moreover, CD34(+)CD38(-) cells 
      had self-renewal potential. We found that leukemic stem-like cells from KG1a 
      cells were resistant to chemotherapy and NK-mediated cytotoxicity. NKG2D ligands 
      involve in protecting LSCs from NK-mediated attack. Taken together, our studies 
      provide a novel cell model for leukemic stem cells research. Our data also shed 
      light on mechanism of double resistant to chemotherapy and NK cell immunotherapy, 
      which was helpful for developing novel effective strategies for LSCs.
CI  - Copyright A(c) 2011 Elsevier Ireland Ltd. All rights reserved.
FAU - She, Miaorong
AU  - She M
AD  - Department of Hematology, Guangdong General Hospital, Guangdong Academy of 
      Medical Sciences, Guangzhou, People's Republic of China. shemiaorong@hotmail.com
FAU - Niu, Xinqing
AU  - Niu X
FAU - Chen, Xilin
AU  - Chen X
FAU - Li, Jinggao
AU  - Li J
FAU - Zhou, Maohua
AU  - Zhou M
FAU - He, Yanjie
AU  - He Y
FAU - Le, Yi
AU  - Le Y
FAU - Guo, Kunyuan
AU  - Guo K
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20111221
PL  - Ireland
TA  - Cancer Lett
JT  - Cancer letters
JID - 7600053
RN  - 0 (Antigens, CD34)
RN  - EC 3.2.2.6 (ADP-ribosyl Cyclase 1)
SB  - IM
MH  - ADP-ribosyl Cyclase 1/immunology
MH  - Antigens, CD34/immunology
MH  - Cell Line, Tumor
MH  - Cell Proliferation
MH  - *Cytotoxicity, Immunologic
MH  - Flow Cytometry
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Killer Cells, Natural/*immunology
MH  - Leukemia, Myeloid, Acute/immunology/*pathology
MH  - Neoplastic Stem Cells/immunology/*pathology
EDAT- 2011/12/27 06:00
MHDA- 2012/04/28 06:00
CRDT- 2011/12/27 06:00
PHST- 2010/12/07 00:00 [received]
PHST- 2011/11/07 00:00 [revised]
PHST- 2011/12/07 00:00 [accepted]
PHST- 2011/12/27 06:00 [entrez]
PHST- 2011/12/27 06:00 [pubmed]
PHST- 2012/04/28 06:00 [medline]
AID - S0304-3835(11)00764-6 [pii]
AID - 10.1016/j.canlet.2011.12.017 [doi]
PST - ppublish
SO  - Cancer Lett. 2012 May 28;318(2):173-9. doi: 10.1016/j.canlet.2011.12.017. Epub 
      2011 Dec 21.